NCEL logo

NCEL
NewcelX Ltd.

6,010
Mkt Cap
$11.35M
Volume
40,272.00
52W High
$30.80
52W Low
$1.83
PE Ratio
-0.14
NCEL Fundamentals
Price
$2.53
Prev Close
$2.49
Open
$2.50
50D MA
$2.60
Beta
0.66
Avg. Volume
21,734.85
P/B
0.37
Loading...
Loading...
News
all
press releases
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance...
PR Newswire·1mo ago
News Placeholder
More News
News Placeholder
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR...
PR Newswire·2mo ago
News Placeholder
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and...
PR Newswire·2mo ago
News Placeholder
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression...
PR Newswire·3mo ago
News Placeholder
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes...
PR Newswire·3mo ago
News Placeholder
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in...
PR Newswire·4mo ago
News Placeholder
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute NewcelX Strengthens Scientific Advisory Board...
PR Newswire·5mo ago
News Placeholder
NewcelX CEO Issues Letter to Shareholders
NewcelX CEO Issues Letter to Shareholders NewcelX CEO Issues Letter to Shareholders PR Newswire ZURICH, Nov. 4, 2025 ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss...
PR Newswire·5mo ago
News Placeholder
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger PR Newswire ZURICH and NESS ZIONA, Israel, Oct. 30...
PR Newswire·5mo ago
<
...
1
>

Latest NCEL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.